Metformin pharmacogenomics: current status and future directions. - Wikidata - awgldk - TriplyDB

Metformin pharmacogenomics: current status and future directions.

Metformin pharmacogenomics: current status and future directions.

http://www.wikidata.org/entity/Q33959731

about

Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis Cardiovascular safety of anti-diabetic drugs Insulin sensitivity and complications in type 1 diabetes: New insights Using EHR-Linked Biobank Data to Study Metformin Pharmacogenomics.Autophagy and its link to type II diabetes mellitus Metformin pharmacogenomics: biomarkers to mechanisms.Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities.Racial ethnic differences in type 2 diabetes treatment patterns and glycaemic control in the Boston Area Community Health Survey Effects of preventative application of metformin on bile acid metabolism in high fat-fed/streptozotocin-diabetic rats.Activation of the cAMP-PKA pathway Antagonizes Metformin Suppression of Hepatic Glucose Production.Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans.Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases.Using Personalized Medicine in the Management of Diabetes Mellitus.Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?Metformin: A Hopeful Promise in Aging Research.Metformin; a review of its history and future: from lilac to longevity.Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.Inhibition of AMP Kinase by the Protein Phosphatase 2A Heterotrimer, PP2APpp2r2d.Potential and real 'antineoplastic' and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females.The Application of Genomics in Diabetes: Barriers to Discovery and Implementation.An Oral Load of [13C3]Glycerol and Blood NMR Analysis Detect Fatty Acid Esterification, Pentose Phosphate Pathway, and Glycerol Metabolism through the Tricarboxylic Acid Cycle in Human Liver.Limited sampling strategy for determining metformin area under the plasma concentration-time curve.Unexpectedly long half-life of metformin elimination in cases of metformin accumulation.Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus Precision Medicine for Endocrinology.Precision medicine for managing diabetes Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.INFLUENCE OF PHARMACOGENETIC POLYMORPHISMS AND DEMOGRAPHIC VARIABLES ON METFORMIN PHARMACOKINETICS IN AN ADMIXED BRAZILIAN COHORT.Activation of AMP-activated protein kinase by metformin ablates angiotensin II-induced endoplasmic reticulum stress and hypertension in mice in vivo.The pharmacogenetics of metformin.The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial.Epigenetic Control of Pancreatic Regeneration in Diabetes Post-mortem analysis of lactate concentration in diabetics and metformin poisonings

P2860

Q26738743-B4CB7E72-C534-43DA-A82A-2B596C3E5B61 Q26741082-00E91331-A43D-4DCF-9D60-BD1D85729B3C Q27000205-D3364C22-7497-4E61-B9CE-EB8648A24433 Q30955177-0DA43499-3AEE-4C10-9EBB-43FF1AB39237 Q33821526-A029416F-E3D3-4F9F-9267-50155EB8AE0F Q33959783-3CA2207B-153D-4367-84BE-6F23DF5033BE Q34532529-C6210DBE-4711-48D8-9258-DD5E934AB9D3 Q35604695-E434C84D-97C6-4071-B744-0B8CCCD7ADA3 Q35854208-08E45DEC-6EEC-4858-8C7F-CEA961B0740C Q36898203-421DDD63-4069-463E-BFC1-F40D3BE916DE Q36999783-42E1EBCA-6688-44A8-BE5E-15F8922B407A Q37222650-8C78669B-7EE6-48BA-BE91-07F0E3E2BEE2 Q38286999-645F145A-A131-4082-949A-445BE06B72F8 Q38666166-47A1995F-DFEB-498F-82F3-F76CAB809202 Q38692092-18DF9F16-F4EF-4242-AB51-2915D79C387A Q38707185-B9817E5D-A9A6-458A-9247-8C5B5F9070DE Q38747416-8F4AA29A-A454-4833-91D8-B9045125DA7E Q38756907-E0039587-B305-4542-B2A0-8B75FBF573DA Q38774878-65B40E29-B687-4BE4-AC7C-C3A7D86B1E3D Q38816602-578AEA5D-AAEC-452B-AAC2-0B501EB8022C Q38908236-F747FD5C-2C8B-44FD-891F-238563558079 Q39030844-5EB9DAD2-827A-418B-8D93-EE6C949FA14C Q39123582-109EAF06-84BA-4E8C-BA1B-0DA56DDD1434 Q39586521-B51CDE19-8A49-470B-8CDB-C7A930C9DA87 Q39669192-FBA55C6C-F89C-4B1F-986D-757DD71449FD Q40576764-DA8CADE5-7145-4144-9CC1-0BD9BD332972 Q40827759-BE5D0B1C-77A0-448E-B9FC-18849E11E0FE Q41242150-1E7FCA02-BF90-401D-A001-706B913E4D25 Q42332698-2DA732E5-F824-4216-A240-023600C4251A Q42346029-B046A5A7-BF01-44E3-B9FD-B1BE91403D77 Q48099965-DA2BDB16-04A4-4771-A789-EE1F8AB40499 Q48202910-ADF9C182-737C-47A7-A368-006D3CE7D268 Q48242829-B6D6E9D7-3CE7-45E9-AF2C-B7D530E1F2B7 Q48610822-75FA5A75-BD57-49C7-98F1-37E140AB6116 Q53728238-F7FB321C-92E5-4D89-9396-B593C11C6D4A Q58758443-7EC28AFB-9F07-4A9E-9FBF-65E4F35A1DD4 Q58800699-0B3E9759-794E-46D4-9230-7664D754F182

P2860

Metformin pharmacogenomics: current status and future directions.

http://www.wikidata.org/entity/Q33959731

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Metformin pharmacogenomics: current status and future directions.

@ast

Metformin pharmacogenomics: current status and future directions.

@en

type

label

Metformin pharmacogenomics: current status and future directions.

@ast

Metformin pharmacogenomics: current status and future directions.

@en

prefLabel

Metformin pharmacogenomics: current status and future directions.

@ast

Metformin pharmacogenomics: current status and future directions.

@en

P1433

Q33959731-11C9321B-785A-4498-AB0F-E6E47DCA2AF3

P1476

Q33959731-31179D72-6A11-4637-961F-903F125B28A5

P2093

Q33959731-4A794D0B-4E80-4DFF-8FF1-F01A6CEA4327

Q33959731-53FB09A3-E732-4DB5-92ED-935AFBE05752

Q33959731-94E5F4B9-1B68-418C-832F-25A7F400E47D

Q33959731-D17E77A2-4161-44E6-91F7-C8D6040431DF

P2860

Q33959731-048BDD83-EB61-4EF0-B817-A1AF7EDD2A48

Q33959731-0A25EB84-E0E3-4D51-B37B-E99DB6820989

Q33959731-1A36EA5D-50B6-44DC-8FF9-6E148B9686D0

Q33959731-2270FE65-BFCF-440A-8540-137C85EA54C3

Q33959731-27C273A0-CEBD-4E2D-9818-4A871E112330

Q33959731-283BE32B-5F06-42E4-996B-1242CA48FC88

Q33959731-335A7E46-C4D0-4432-8E90-D2ACB33D98B3

Q33959731-37D4F0DB-14C1-4C13-889A-6BBFF168A39E

Q33959731-38B21210-EC07-436A-97A9-382D88F0CA9A

Q33959731-3FACF810-29D9-47FF-89A4-31FCF8062D59

P304

Q33959731-B96AE10D-8CF9-4A29-A24D-AF4D473EB107

P31

Q33959731-B3D97962-14D4-4D23-8792-7E34FE69B645

P356

Q33959731-D85D405B-4FCE-4D61-BDE7-3415F0FE82C2

P407

Q33959731-A854F2EA-D266-435F-AFC3-268C5FE9F9E0

P433

Q33959731-8C0FAFD8-B0A9-4F69-B68E-E5DA3B2D039F

P478

Q33959731-34276640-B576-45B4-9783-6F5EF400CD1F

P50

Q33959731-C7A2D527-A20E-4565-9BB8-319E6D739F37

P577

Q33959731-5BD71010-6952-45A7-97CF-40A31D9BA952

P5875

Q33959731-B97FF961-4B88-477E-ACE4-972AF2BD7B8D

P698

Q33959731-B2B30D49-178A-40AF-9A23-A96AEFAF2FD7

P921

Q33959731-5A9CCE41-7397-409A-9436-71C1261A4A2D

Q33959731-EA4F3E82-F25C-4DAF-87CD-B0F148D63841

P932

Q33959731-1BEE10CD-426E-4763-BA5D-30A453C2D294

P356

P1433

P1476

Metformin pharmacogenomics: current status and future directions.

@en

P2093

Aaron C Pawlyk

http://www.w3.org/2001/XMLSchema#string

Catherine McKeon

http://www.w3.org/2001/XMLSchema#string

Jose C Florez

http://www.w3.org/2001/XMLSchema#string

Kathleen M Giacomini

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Standards of medical care in diabetes--2014

The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future

P304

2590-2599

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB13-1367

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

Alan R. Shuldiner

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264248043

http://www.w3.org/2001/XMLSchema#string

P698

25060887

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

4113063

http://www.w3.org/2001/XMLSchema#string